A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

2019102 citationsJournal Articlegold Open Access

Authors

( ClinicalTrials.gov Identifier: NCT02028442 ). Trial registration date: 07 January 2014 - Retrospectively registered.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 7, Issue 1, pp. 20-20

Field-Weighted Citation Impact: 10.57